Ascelia Pharma Logo

Ascelia Pharma

ACE | ST

Overview

Corporate Details

ISIN(s):
SE0010573113 (+2 more)
LEI:
5493002YR9VCJJPWYN08
Country:
Sweden
Address:
Hyllie Boulevard 34, 215 32 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ascelia Pharma is a biotechnology company dedicated to the development and commercialization of novel drugs for rare cancer conditions (orphan oncology). The company's vision is to address unmet medical needs by advancing a portfolio of innovative therapies with clear development and market pathways. Its lead product candidate, Orviglance, is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI) designed to improve the detection of liver metastases in cancer patients with severely impaired kidney function, for whom gadolinium-based agents are contraindicated. The company is focused on progressing its pipeline through clinical development and towards regulatory approval.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ascelia Pharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-21 07:30
Interim Report
Swedish 4.5 MB
2025-08-21 07:30
Interim Report
English 4.4 MB
2025-05-16 07:30
Interim Report
Swedish 4.4 MB
2025-05-16 07:30
Investor Presentation
English 4.4 MB
2025-05-07 16:30
Post-Annual General Meeting Information
Kommuniké från årsstämma den 7 maj 2025 i Ascelia Pharma AB
Swedish 193.2 KB
2025-05-07 16:30
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
English 192.7 KB
2025-04-30 11:30
Declaration of Voting Results & Voting Rights Announcements
Change in Number of Shares and Votes in Ascelia Pharma AB
English 185.4 KB
2025-04-30 11:30
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Ascelia Pharma AB
Swedish 185.6 KB
2025-03-18 22:05
Legal Proceedings Report
Ascelia Pharma meddelar positivt utfall från FDA-möte och bekräftar planen att …
Swedish 190.7 KB
2025-03-18 22:05
Legal Proceedings Report
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to …
English 190.5 KB
2025-02-25 14:45
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma den 25 februari 2025 i Ascelia Pharma AB
Swedish 191.1 KB
2025-02-25 14:45
Post-Annual General Meeting Information
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 Febr…
English 190.5 KB
2025-02-12 21:30
Board/Management Information
Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB
English 191.2 KB
2025-02-12 21:30
Pre-Annual General Meeting Information
Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2025
Swedish 191.0 KB
2025-02-07 07:30
Annual / Quarterly Financial Statement
Swedish 4.0 MB

Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ascelia Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-22 Marie Birgitta Källström Other Other 18,752 40,316.80 SEK
2025-04-15 Niels Mengel Other Other 92,304 198,453.60 SEK
2025-04-15 Peter Benson Other Other 50,000 107,500.00 SEK
2025-04-15 Carin Linde Other Other 40,328 86,705.20 SEK
2025-04-15 Peter Benson Other Other 21,688 46,629.20 SEK
2025-04-15 Peter Benson Other Other 20,472 44,014.80 SEK
2025-04-15 Julie Brogren Other Other 18,000 38,700.00 SEK
2025-04-15 Peter Benson Other Other 6,152 13,226.80 SEK
2024-09-03 KIBEGEON Other Sell 913,545 150,917.63 SEK
2024-09-03 Niels Mengel Other Sell 131,965 17,815.28 SEK

Peer Companies

Company Country Ticker View
Adocia Logo
Developing novel drug formulations for metabolic diseases like diabetes and obesity for out-licensing.
France ADOC
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs for cancer, with a lead candidate for pancreatic cancer.
Sweden ATORX
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
AlzeCure Pharma Logo
Clinical-stage pharma developing drugs for CNS diseases like Alzheimer's and pain.
Sweden ALZCUR
Alzinova AB Logo
Develops immunotherapies and vaccines to treat and prevent Alzheimer's disease.
Sweden ALZ
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
Annexin Pharmaceuticals AB Logo
Clinical-stage biotech developing Annexin A5 protein therapies for ophthalmology and oncology.
Sweden ANNX
Aptahem AB Logo
Develops RNA-based aptamer drugs for acute, life-threatening conditions like sepsis.
Sweden APTA
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA